Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors

NCT03245450 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03245450
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245450 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
March 5, 2018
Completion date
May 17, 2021
Enrollment
40 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, non-rhabdomyosarcoma soft tissue sarcoma, refractory or recurrent solid tumors, rhabdomyosarcoma